Tracking Blood Sugar Changes During Treatment for Ketosis-Prone Diabetes
Studies day-to-day blood sugar changes in adults with ketosis-prone diabetes using glucose monitors and insulin.
Key facts
- Who runs it
- Emory University
- Where
- Atlanta, United StatesSee the 2 sites
- Trial code
- Registry title
- Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 12 people, planned
- Started
- 23 Jan 2025
- Expected to end
- Jan 2027
- Type of study
- Interventional
- Treatments tested
- Continuous Glucose Monitoring
- Insulin
- Record updated
- 15 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults of African American ancestry with a BMI of 28 kg/m2 or more who have diabetic ketoacidosis (DKA) from ketosis-prone diabetes, to track blood glucose during treatment toward remission.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Diabetic ketoacidosis (DKA) with plasma glucose > 250 mg/dl (13.9 mmol/L), venous pH < 7.30, serum bicarbonate < 18 mmol/l and serum ketones (beta-hydroxy butyrate) > 1.5 mmol/L. Diabetes diagnosed no more than 90 days before the DKA.
Main reasons for not taking part
- Significant medical or surgical illness, such as heart problems, chronic kidney or liver problems, or infections
- Uncontrolled endocrine disorders such as hypercortisolism, acromegaly or hyperthyroidism
- Anemia, bleeding disorders or abnormal coagulation tests
- Pregnant
- Unable to give consent
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Provide informed consent
- Have a BMI ≥ 28 kg/m2
- Be of African American ancestry
- Meet diagnostic criteria for DKA. Diagnostic criteria for DKA will include a plasma glucose > 250 mg/dl, a venous pH < 7.30, a serum bicarbonate < 18 mmol/l, and serum ketones (beta-hydroxy butyrate) > 1.5 mmol/L
Who cannot take part
- Diagnosis of diabetes > 90 days before the presentation of DKA
- Have recognized uncontrolled endocrine disorders such as hypercortisolism, acromegaly, or hyperthyroidism
- Significant medical or surgical illness including but not limited to myocardial ischemia, congestive heart failure, chronic peripheral venous insufficiency, chronic renal insufficiency, liver insufficiency (serum transaminases 3 times the upper limit of normal) and acute or chronic infectious processes
- Anemia (hemoglobin < 12.5 g/dL for men, <11.5 gm/dL for women), bleeding disorders, or abnormalities in coagulation studies
- Pregnant
- Unable to give consent
Where in United States
- Emory University Hospital MidtownAtlanta, United StatesContact: Priyathama Vellanki, MD, MSTaking people
- Grady Health SystemAtlanta, United StatesContact: Priyathama Vellanki, MD, MSTaking people
About the trial
What the trial wants to find out
The goal of this study is to quantify day-to-day changes in blood glucose during treatment towards remission in ketosis-prone diabetes (KPDM) and describe them using a mathematical model of KPDM pathogenesis and remission.
The group in the trial
- Continuous Glucose Monitoring with Adjusted Insulin DosesTreatment being tested
Patients with ketosis-prone diabetes will wear a continuous glucose monitor (CGM) from the time of hospital discharge until insulin discontinuation. Insulin doses will be adjusted based on CGM glucose readings.
Treatment: Continuous Glucose Monitoring and Insulin
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity
- Plain-language title
- Tracking Blood Sugar Changes During Treatment for Ketosis-Prone DiabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 15 June 2026